CHAIR
:
SPEAKER
(S):
Barrie Carter, PhD, Executive Vice President & CSO, Targeted Genetics Corporation
Terry Flotte, MD, Dean, University of Massachusetts Medical School
Douglas Jolley, PhD, EVP of Research and Product Development
Robert Sobol, MD, Senior VP, Medical & Scientific Affairs, Introgen Therapeutics, Inc
Description
"Gene therapy could be the next medical breakthrough. The promise of the technology to change the lives of patients is enormous—treatments for diseases with no cure and new
approaches to ailments that have proven resistant to traditional approaches. However, more than ten years of research in this area has yet to deliver an approved drug, and public perception is increasingly based on myth versus science. Researchers, physicians and an industry analyst will discuss key developments in the gene therapy sector and how close we are to clinical reality. Panelists will also provide an overview of gene therapy and delivery technologies used to deliver gene therapies, including systemic vs. targeted gene therapy."
Objective 1: Differentiate the various technologies and review the risks and benefits of each approach.
Objective 2: Review the regulatory challenges of gene therapy.
Objective 3:Discuss promising gene therapy candidates and their development timelines.